Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Form 4 overview: Executive Chairman and Director Matthew Rabinowitz of Natera, Inc. (NTRA) reported a series of six open-market sales executed by his spouse between 15 May 2025 and 13 Jun 2025.
- Total shares sold: 54,000
- Sale prices: $150.20 – $165.85
- Approximate gross proceeds: ≈ $8.4 million
- Indirect share balance (spouse): reduced from 74,000 to 30,000
- Direct ownership (Rabinowitz): 2,362,570 shares unchanged
No derivative transactions were reported, and the filing does not indicate a Rule 10b5-1 trading plan. The sales represent a 73% reduction of the spouse’s holdings but leave the insider with a substantial direct stake, suggesting continued alignment with shareholders despite the liquidity event.
Form 4 Overview – Natera, Inc. (NTRA)
The filing discloses that co-founder and director Jonathan Sheena sold Natera common stock on two separate dates under previously adopted Rule 10b5-1 trading plans.
- 18 Jun 2025: Direct sale of 3,070 shares at a weighted-average price of $167.2869 per share. Direct ownership after the sale is 248,774 shares.
- 16 Jun 2025: Eight block sales by Caraluna 1 Trust and Caraluna 2 Trust (both held for the benefit of trust beneficiaries and disclaimed for beneficial-ownership purposes). The trusts sold an aggregate of 3,000 shares at weighted-average prices ranging from $162.04 – $165.55 per share. Post-transaction holdings were 38,379–37,282 shares per trust line item.
No derivative security transactions were reported. All sales were executed automatically under the trading plans adopted on 11 Dec 2024 (direct holdings) and 7 Jun 2024 (trust holdings), limiting discretionary timing by the insider.
In total, the reporting person disposed of 6,070 shares, representing a low-single-digit percentage of his reported direct and indirect ownership. While insider selling can be perceived negatively, the modest size relative to the remaining stake and the use of pre-arranged 10b5-1 plans mitigate signal risk.